Historical Press Releases:
The press releases posted on this Site are current
only as of their date. Nventa Biopharmaceuticals does not update its press releases
solely due to a change in the facts described in old press releases.
Old press releases are provided only to give readers a sense of
past developments and should not be taken as implying that the information
contained in them remains accurate. Prior to June 1 2006, Nventa Biopharmaceuticals Corporation was named Stressgen Biotechnologies Corporation
Press Releases 2002
 October
24, 2002 - Stressgen Biotechnologies Reports Third Quarter 2002
Financial Results
October 7, 2002
- Stressgen Announces Presentation on New Phase II HspE7 Data on
Genital Warts and Anal Dysplasia at HPV 2002
 October 7, 2002
- Stressgen Announces Presentation of Data on the Mechanism for
the Immunotherapeutic Activity of HspE7 at HPV 2002
October 7, 2002
- Stressgen Announces Presentation of Data on the Mechanism for
the Immunotherapeutic Activity of HspE7 at HPV 2002
October 7, 2002
- Stressgen Announces Presentation of Data on the Mechanism for
the Immunotherapeutic Activity of HspE7 at HPV 2002
September
24, 2002 - Stressgen Biotechnologies Announces Elizabeth Greetham
Appointed to Board of Directors
August
8, 2002 - Stressgen Biotechnologies Announces Completion of Enrollment
in Phase II Clinical Trial of HspE7 for Recurrent Respiratory Papillomatosis
in Children - Orphan Drug Status for RRP May Provide Fastest Route
to Market
August
7, 2002 - Stressgen Biotechnologies Announces Second Quarter 2002
Financial Results
July
16, 2002 - Stressgen Biotechnologies Appoints Dr. Margot Northey
to Board of Directors
July
10, 2002 - Stressgen Appoints Vice Presidents of Regulatory Affairs
and Clinical Development - Company Increases Depth of Senior Management
Team to Accommodate Pipeline Development and Roche Partnership
June
24, 2002 - Stressgen Biotechnologies and Roche Announce Global Development
and Marketing Collaboration Valued Up To $204 Million U.S.
May
22, 2002 - Stressgen Strengthens Board with Canadian MDS Executive
Ian Lennox
May
7, 2002 - Stressgen Biotechnologies Reveals new Aspects of Mechanism
of Action for HspE7 and Confirms Immunostimulatory Capabilities
of Platform Technology for Hepatitis B Virus
May
2, 2002 - Stressgen Biotechnologies Announces First Quarter 2002
Financial Results
April
17, 2002 - Stressgen Invites you to Participate in its First Quarter
2002 Conference Call Thursday May 2, 2002 at 4:00 p.m. Eastern;
1:00 p.m. Pacific
February
12, 2002 - Stressgen Biotechnologies Announces 2001 Financial Results
February
8, 2002 - Stressgen Validates Decision to Agggressively Pursue Genital
Warts Market
January
31, 2002 - Stressgen Invites you to Participate in its Year-End
2001 Conference Call Tuesday, February 12, 2002 at 4:00 p.m. Eastern;
1:00 p.m. Pacific
January
23, 2002 - Stressgen's New European Patent for Heat Shock Protein
Fusions Maximizes International Marketing Opportunities
January
15, 2002 - Stressgen Announces New U.S. Composition Patent Which
Firmly Solidifies Stressgen's Position in Heat Shock Protein Fusion
Technology
January
04, 2002 -Stressgen Announces Issuance of U.S. Patent Solidifying
its Heat Shock Protein-Based Technology Platform
|
